Cargando…

Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers

BACKGROUND: The individual features of tumours are often disregarded in cohort studies. As these features may represent a source for individualised cancer treatment, it is important to develop a novel approach for their assessment. METHODS: We used proteomics, systems biology, and immunohistochemist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Attarha, S, Andersson, S, Mints, M, Souchelnytskyi, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738137/ https://www.ncbi.nlm.nih.gov/pubmed/23839494 http://dx.doi.org/10.1038/bjc.2013.359

Ejemplares similares

Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy
por: Maeda, J, et al.
Publicado: (2008)

PKN1 modulates TGFβ and EGF signaling in HEC-1-A endometrial cancer cell line
por: Attarha, Sanaz, et al.
Publicado: (2014)

Impact of genomic stability on protein expression in endometrioid endometrial cancer
por: Lomnytska, M I, et al.
Publicado: (2012)

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer
por: Voss, M A, et al.
Publicado: (2011)

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
por: Bignotti, E, et al.
Publicado: (2011)

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
por: Karayan-Tapon, L, et al.
Publicado: (2008)

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
por: Mallett, S, et al.
Publicado: (2010)

Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value
por: Lomnytska, M I, et al.
Publicado: (2011)

Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
por: Pagin, A, et al.
Publicado: (2013)

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
por: Bignotti, E, et al.
Publicado: (2008)

Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy
por: Ikeda, Yuji, et al.
Publicado: (2015)

Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control
por: Seidel, A, et al.
Publicado: (2006)

Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)
por: Andersson, S, et al.
Publicado: (2005)

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
por: Kahlert, C, et al.
Publicado: (2009)

Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation
por: Hiraoka, N, et al.
Publicado: (2010)

Oncofoetal fibronectin – a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma
por: Hesse, E, et al.
Publicado: (2005)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
por: Ino, K, et al.
Publicado: (2006)

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer
por: Matsushita, R, et al.
Publicado: (2015)

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
por: Benoy, I H, et al.
Publicado: (2006)

Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations
por: Pinato, D J, et al.
Publicado: (2013)

Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
por: Seebacher, V, et al.
Publicado: (2012)

Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy
por: Kelly, P, et al.
Publicado: (2010)

Disseminated tumour cells as a prognostic biomarker in colorectal cancer
por: Flatmark, K, et al.
Publicado: (2011)

Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
por: Hiramatsu, Kosuke, et al.
Publicado: (2016)

pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant
por: Brunner, A, et al.
Publicado: (2012)

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer
por: Lugli, A, et al.
Publicado: (2009)

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
por: Lee, H E, et al.
Publicado: (2008)

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
por: Goeppert, B, et al.
Publicado: (2013)

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study
por: Vijayvergia, Namrata, et al.
Publicado: (2016)

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer
por: Kelly, P, et al.
Publicado: (2012)

Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells
por: Yamamoto, K, et al.
Publicado: (2012)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)

Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse
por: Lu, C-Y, et al.
Publicado: (2011)

Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity
por: McClelland, C M, et al.
Publicado: (2007)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
por: Sjöberg, Elin, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gen70qs4e3o7mvupt8j7av02vo